This study demonstrated that interventional therapy (125I seed strand and PVS implantation plus TACE) combined with systemic therapy (lenvatinib plus anti-PD-1 antibody) is a safe and effective treatment strategy for HCC patients with Vp4 PVTT. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.